June 2004
Clinical Infectious Diseases;6/1/2004, Vol. 38 Issue 11, p4
Academic Journal
Fear of bioterrorism has helped the drug manufacturing company Acambis Plc. win contracts worth about $770 million to supply smallpox vaccine to the United States even before marketing authorization. The contracts require phase III clinical trials to continue so that it eventually gains a product licence. In a statement, Acambis said its independent data and safety monitoring board had recommended that enrollment be suspended after three suspected cases of myopericarditis were discovered among 1132 persons vaccinated for the first time.


Related Articles

  • SMALLPOX, WEST NILE VACCINES UNDER DEVELOPMENT.  // Clinical Infectious Diseases;11/1/2001, Vol. 33 Issue 9, pii 

    Unveils the plan of Acambis Plc to start clinical trials on smallpox vaccine in the United States in 2002. Information on the vaccine.

  • Bioterrorism threat becomes reality. Ready, Tinker // Nature Medicine;Nov2001, Vol. 7 Issue 11, p1167 

    Reports on the request of the U.S. Health & Human Services Secretary Tommy Thompson to Acambis to speed up the development of its smallpox vaccine amid the threat of bioterrorism attacks. Schedule of the production of vaccine for clinical trials; Cause of smallpox; Development of a smallpox...

  • Acambis shares tumble after trial suspension.  // PharmaWatch: Biotechnology;June 2004, Vol. 3 Issue 6, p8 

    Reports on the suspension of the clinical trials of a new smallpox vaccine conducted by Acambis PLC due to side-effect concerns in the U.S. Design of the trials to compare the safety, tolerability and efficacy of the smallpox vaccine; Availability of the vaccine.

  • Acambis smallpox vaccine awarded second US government contract.  // PharmaWatch: Biotechnology;November 2004, Vol. 3 Issue 11, p17 

    Announces that Great Britain-based biotechnology firm Acambis has been awarded a contract from the U.S. National Institute of Health for the manufacture and development of a smallpox vaccine. Acambis' partnership with Baxter Healthcare on the project; Split of the National Institute of Allergy...

  • The Pros and Cons of Project BioShield.  // Pharmaceutical Executive;Oct2004, Vol. 24 Issue 10, p36 

    Interviews Acambis Chief Executive Officer Gordon Cameron about the pros and cons of contracting with the United States government for the development of biodefense products. Availability of fundsfor the BioShield project; Start of clinical tests on a smallpox vaccine; Preconditioning of the...

  • pharmaceuticals In Brief.  // Chemical Market Reporter;9/27/2004, Vol. 266 Issue 10, p10 

    Reports development in the pharmaceutical industry as of September 2004 in the U.S. Completion of the review of phase III trials for second-generation smallpox vaccine by Acambis PLC; Launch of the C3-TunePhos, a proprietary, versatile chiral catalyst, from Chiral Quest Inc.; Acquisition of PMP...

  • CDC Orders 209 Million Doses of Smallpox Vaccine.  // BioPharm International;Nov2002, Vol. 15 Issue 11, p14 

    Announces that Acambis has produced the first doses of final, filled and kitted smallpox vaccine for the U.S. Centers for Disease Control and Prevention stockpile. Acambis use of the same vaccinia virus strain used in the global effort to eradicate smallpox in the 1870s in producing two...

  • Acambis/Baxter Get Smallpox Contract.  // Chemical Market Reporter;12/03/2001, Vol. 260 Issue 21, p4 

    Focuses on the contract awarded by the United States government to Acambis PLC and Baxter International Inc. for smallpox vaccines. Value of the contract; Other companies considered for the contract; Terms of the contract.

  • Bavarian Lands $545M Deal For Smallpox Vaccine Stockpile. Sheridan, Cormac // BioWorld International;4/18/2007, Vol. 12 Issue 16, p1 

    The article announces that Bavarian Nordic A/S is poised to land a contract to supply the U.S. government with a stockpile of 20 million doses of its next-generation smallpox vaccine Imvamune. The value of the deal is mentioned. Bavarian Nordic's rival company is Acambis plc. Comments from Rolf...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics